Ngā Kāwai katoa
EN

Kaainga>Products>Nga Hua Toi Taputapu Oti>Cardiovascular me te Urinary

Te Werohanga Waikawa Tranexamic


Whakaatu

Taipitopito Tere:

2ml: 0.2g

10 amps/pouaka

 

Tautoko OEM / ODM:Āe

MOQ:500,000 Amaha

Wā Tukunga:30 ~ 55 Ra

Term Trade:FOB, CIF

Term utu:T / T, L / C

Paerewa Wātea:CP,BP

Tuhinga:GMP,CPP,FSC,CTD

 

Tuhinga

1. This product is primarily used for all types of bleeding due to acute or chronic, limited or systemic primary fibrinolysis. It is generally not used in secondary hyperfibrinolytic states caused by disseminated intravascular coagulation prior to heparinization.

2. For trauma or surgical bleeding in fibrinogen-rich organs such as prostate, urethra, lung, brain, uterus, adrenal gland and thyroid.

3. Used as an antagonist of tissue-type fibrinogen activator (t-PA), streptokinase and urokinase.

4. For fibrinolytic bleeding due to miscarriage, early placental abruption, stillbirth and amniotic fluid embolism, and increased menorrhagia due to localized fibrinolytic lesions in the uterine cavity.

 

Nga tauhohenga kino

1. Occasionally, there is intracranial thrombosis and bleeding due to drug overdose.

2.There may be diarrhea, nausea, and vomiting.

3.Less commonly, there is menstrual discomfort (due to blood clotting during menstruation).4 Because the product can enter the cerebrospinal fluid, central nervous system symptoms such as blurred vision, headache, dizziness, and fatigue may occur after injection, especially in relation to the rate of injection, but are rare.

 

 

 

Tuhinga

Whakaorangia ki te waahi makariri, maroke me te pouri.

Tiakina nga rongoa katoa mai i nga tamariki.

 


Ikātahi